Abstract
Homeostasis in the ileum, which is commonly disrupted in patients with Crohn’s disease, involves ongoing immune responses. To study how homeostatic processes of the ileum impact CD4+T cell responses, we used TCR transgenic tools to breed mice that spontaneously produced CD4+T cells reactive to an antigen expressed in the ileum. At an early age, the ilea of these mice exhibit crypt hyperplasia and accumulate increased numbers of TH17 cells bearing non-transgenic clonotypes. Half of these mice subsequently developed colitis linked to broad mucosal infiltration by TH17 and TH1 cells expressing non-transgenic clonotypes, chronic wasting disease and loss of ileal crypt hyperplasia. By contrast, adult mice with normal growth continued to exhibit TH17-associated ileal crypt hyperplasia and additionally accumulated ileal-reactive Treg cells. Both IL-17A and IFNγ were protective, as their deficiency precluded ileal-reactive Treg accumulation and exacerbated colitic disease. IL-23R blockade prevented progression to colitis, whereas nTreg cell transfers prevented colitic disease, ileal crypt hyperplasia and ileal-reactive Treg accumulation. Thus, our studies identify an IL-17A and IFNγ-dependent homeostatic process that mobilizes ileal-reactive Treg cells and is disrupted by IL-23.
INTRODUCTION
Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is a collection of human disorders characterized by a breakdown in mucosal tolerance1. Biologic therapies targeting TNFα and other immunosuppressive interventions can induce remission. However, some patients remain refractory, relapses are common, and many patients demonstrate a loss of efficacy with time2,3. A more complete understanding of IBD immunopathogenesis is needed to develop new therapies that reduce inflammation while simultaneously restoring durable mucosal tolerance.
In Crohn’s disease, both TH1 and TH17 cells are components of the inflammatory lesions and reducing their development with an IL-12p40 neutralizing antibody shows therapeutic efficacy4. By contrast, neutralizing their canonical cytokine products IFN-γ or IL-17A has limited benefit5, with anti-IL-17A treatment increasing adverse events6. These clinical trial results were not predicted by mouse colitis models as IFNγ is generally necessary for pathology7 and IL-17A demonstrates both protective and pathogenic roles in the same model of colitis8,9. Anti-inflammatory regulatory T (Treg) cells also accumulate in IBD lesions10 demonstrating that part of the CD4+T cell accumulation is an attempt to limit disease. It is likely that we underestimate the non-pathogenic contributions of TH1 and TH17 cells, given that many assumptions are based on highly penetrant mouse models with excessive effector TH cell activity.
Immunologic function and homeostatic activity vary across different regions of the gastrointestinal tract11. In contrast to the colon, where dense mucus physically limits microbial access to the epithelium12, the small intestine needs to absorb a broader array of nutrients and the mucus is more permeable13. Paneth cells and their antimicrobial products help limit commensal microbes from penetrating to the epithelial layer in the ileum14,15. This activity is important, as Crohn’s disease risk variants for Nod2, Atg16l1, Kcnn4 and Xbp1 all disrupt anti-microbial production and Paneth cell function16. The ileum also normally hosts CD4+T cells, and TH17 cells in particular can induce epithelial anti-microbial production via their secreted cytokine products, including IL-17A17. Further limiting mucus penetration, commensal microbes of the small intestine are more extensively coated by IgA than their colonic counterparts18. This IgA maintains tolerance to commensal microbes and in part requires both resident Treg and TH17 cells19–22. Thus, the ileum demonstrates homeostatic CD4+T cell activity that is important for establishing and maintaining tolerance to the commensal microbiota. Understanding these beneficial immune responses is key for developing IBD therapies that do not interfere with the long-term restoration of tolerance.
We sought to study homeostatic adaptive immune responses in the ileum to better understand the immunopathogenesis of Crohn’s disease, which most commonly manifests at this site. Unfortunately, most mouse models of enterocolitis do not show ileal inflammation and those available pose challenges for the study of the non-pathogenic activity of CD4+T cells. To circumvent these limitations, we developed a mouse line expressing a model antigen in the ileum and bred it to an antigen-specific CD4+T cell receptor transgenic line. This yielded an incompletely penetrant model of colitis and identified a non-pathogenic TH17-associated ileal process that required both IL-17A and IFNγ for tolerance of the ileal model antigen.
RESULTS
To study immune responses in the ileum, we generated a transgenic mouse system that combined ileal expression of a model antigen with antigen-specific TCR transgenic mice. We used the well-characterized antigen hen egg lysozyme (HEL) fused to the transmembrane region of Ld (mHEL) and expressed this construct under control of the human defensin 5 (HD5) promoter (HD5-mHEL; Figure S1A). Transgenic HD5-mHEL mice expressed mHEL mRNA product only among cells at ileal crypt bases and not the colon or duodenum (Figure S1B–D). To study if HD5-mHEL expression would draw HEL-reactive CD4+T cells to the ileum, we sorted CD4+CD8α−Foxp3− (Tconv) cells from Rag1−/− mice carrying the HEL(46–61)-reactive 3A9 transgenic TCR and transferred 1×106 CD4+3A9+T cells into HD5-mHEL Rag1−/− mice and Rag1−/− controls. After seven days, transferred CD4+3A9+Tconv cells were found in higher abundance in ilea of HD5-mHEL Rag1−/− recipients than Rag1−/− controls and were also more abundant than CD4+Tconv cells in ilea of untreated WT B6.AKR controls. In ~50% of HD5-mHEL Rag1−/− recipients we recovered more 3A9+T cells from the ileum than were provided in the original transfer dose (Figure S1E). Though colons from HD5-mHEL+/−Rag1−/− recipients contained more CD4+3A9+T cells than the colons of Rag1−/− controls, this accumulation was less than the normal abundance of CD4+Tconv cells in untreated WT colons and ~100-fold less than the original transfer dose (Figure S1E). Together, these results indicate that the HD5-mHEL transgene exhibits expression that is limited to the base of ileal crypts and is sufficient to promote ileal-specific accumulation of mHEL-reactive Tconv cells.
Early spontaneous TH17-associated ileal hyperplasia gives way to an incompletely penetrant TH17 & TH1-associated colitis
To create mice with spontaneous ileal CD4+T cell self-reactivity, we crossed 3A9+/− mice to HD5-mHEL+/− mice and studied them at 4 discrete time points (Figure 1A). At weaning, all genotypes had a similar weight, however by the juvenile age (50±7 days old), 3A9+/−HD5-mHEL+/− progeny (‘Bigenic’ genotype) weighed less than age-matched littermate controls (Figure 1B). Similarly, circulating CD4+TEM cells of Bigenic mice went from being less frequent at weaning to almost four times more frequent in juveniles, with the magnitude of this increase highest for the smallest mice (Figure 1C). The Ileal mucosa of juvenile Bigenic mice showed crypt hyperplasia with an average increase in crypt depth of ~35% (Figure 1D), while no difference in Paneth cell abundance was appreciated. Both the ileal lamina propria and mesenteric lymph nodes (mLN) showed increased TH17 cell accumulation (Figure 1E). Serum cytokines provided further indication of a TH17-associated process as IL-6, CCL20, IL-22, IL-17A, IL17F and TNFα were increased (Figure 1F). Though TH17 cells can facilitate neutrophil recruitment23, neutrophil staining in juvenile Bigenic ilea was reduced relative to 3A9 tissue and similar to WT controls (Figure 1G). These findings revealed the presence of a TH17-associated crypt hyperplasia in the ilea of juvenile Bigenic mice that was linked to restricted growth without a concomitant increase in neutrophil accumulation or obvious loss of Paneth cells.
Figure 1. TH17-associated ileal hyperplasia without neutrophil increase in juvenile mice.
(A) Bigenic mouse breeding schematic with ages and age-ranges (‘Weanling age’ 23±2 days; ‘Juvenile age’ 50±7 days; ‘Early Adult age’ 100±7 days; ‘Late Adult age’ 50±7 days; ‘Juvenile age-range’ between weanling and juvenile ages) of mice analyzed in our study.
(B) Mouse weights for WT, 3A9 and Bigenic mice normalized to age and sex (Weight Z-score). Weight at weaning (WT n=491, 3A9 n=155, Bigenic n=338) and at juvenile (WT n=316, 3A9 n=131, Bigenic n=147) ages.
(C) Percent of live circulating cells that are TCRβ+CD4+CD8−Foxp3−CD44+CD62L− (CD4+TEM) for WT, 3A9 and Bigenic mice. Shown at weanling (WT n=271, 3A9 n=36, Bigenic n=118) and juvenile (WT n=28, 3A9 n=18, Bigenic n=37) ages. Correlation to weight Z-score at time of observation for Juvenile Bigenic cohort shown. FACS plot representative of CD4+TEM as a percent of TCRβ+CD4+CD8−Foxp3− cells.
(D) Average Ileal crypt depths for juvenile WT (n=21), 3A9 (n=12) and Bigenic (n=19) mice. Representative crypts lengths shown for WT (104μm, 98 μm), 3A9 (107 μm, 122 μm) and Bigenic (146 μm, 162 μm) ileal tissue.
(E) Numbers of TCRβ+CD4+CD8−Foxp3−IFNg+IL-17A− (TH1) and TCRβ+CD4+CD8−Foxp3−IFNγ−IL-17A+ (TH17) cells accumulating in juvenile WT, 3A9 and Bigenic mice. Numbers from mLN (WT n=24, 3A9 n=19, Bigenic n=21) and ileum (WT n=7, 3A9 n=12, Bigenic n=14) and representative FACS plot shown from Bigenic ileum.
(F) Serum concentrations of TH17-associated cytokines from juvenile WT (n=6), 3A9 (n=6) and Bigenic (n=13) mice. Cytokines IL-6, CCL20, IL-22, IL-17A, IL-17F and TNFα shown.
(G) Percent of mucosal surface with neutrophil immunohistochemical stain from WT (n=21), 3A9 (n=10) and Bigenic (n=18) ileal tissue sections. Representative neutrophil IHC section from Bigenic ileum with neutrophil (green) and counter stain (orange) detection indicated. Scale bar reflects 100 μm.
Next, we studied the evolution of these distinct mucosal features by aging Bigenic mice to 150 days while closely monitoring their weight. We observed an incompletely penetrant and variably expressed weight loss phenotype that frequently exhibited a relapsing and remitting course (Figure 2A). To identify mice with this weight loss or any other growth abnormality (‘symptomatic’), we determined when an individual mouse was 2 standard deviations smaller and had poor growth or experienced 2 standard deviations more weight loss than ~120 WT littermate controls. In contrast to the few control mice that met these criteria, most symptomatic Bigenic (BigenicS) mice continued to lose weight following diagnosis (Figure 2B). By 100 days (‘early adult’ age), approximately 50% of Bigenic mice were symptomatic whereas only 3% of control mice met these criteria (Figure 2C; left). Incidence of weight symptomatology was highest during the juvenile period and declined with age (Figure 2C; right). Thus, half of BigenicS mice diagnosed by 100 days first met criteria within 25 days from weaning. These observations demonstrate the incomplete penetrance of a chronic wasting disease in Bigenic mice and reveal its declining incidence after the juvenile period.
Figure 2. Colitis-associated wasting disease initiates early and loses ileal hyperplasia.
(A) Representative growth curves for two Bigenic mice exhibiting a weight loss phenotype. Dashed vertical line indicates when the mouse first showed two standard deviations more weight loss than age and sex-matched control mice.
(B) Weight change rate following initial manifestation of the wasting phenotype for WT (WTS n=11), 3A9 (3A9S n=7) and Bigenic (BigenicS n=54) mice reaching early adult age.
(C) Prevalence of a wasting phenotype among WT (n=166), 3A9 (n=74) and Bigenic (n=111) mice (left). Linear regression of prevalence vs age from either the juvenile period or from the 50 to 100-day age-range of the Bigenic cohort (slope = incidence).
(D) Ileal crypt depths for late Adult WT (n=32), 3A9 (n=14), BigenicNS (n=11), and BigenicS (n=17) mouse cohorts. BigenicS mouse cohort includes mice euthanized before late Adult age (n=5; median age = 104 days).
(E, F, and G) Numbers of TH17, TH1 and Treg cells from ileum (E), colon (F) and mLN (G). WT (n=15), 3A9 (n=14), BigenicNS (n=10) and BigenicS (n=9) mice from early Adult age studied given the high specificity for diagnosis relative to control mice and the equivalent penetrance of BigenicNS and BigenicS phenotypes.
(H) Colitis scores from cohort shown in panel D. Representative WT (top) and BigenicS (bottom) colonic tissue H&E sections showing crypt hyperplasia (bottom; left), goblet cell loss (bottom; left), submucosal infiltration (bottom; both) and crypt abscesses (bottom; right). Scale bars reflect 250 μm.
The declining incidence of symptomatology with age led us to determine if the mucosal features present in juvenile mice spontaneously resolved in non-symptomatic Bigenic (BigenicNS) mice. Paneth cell abundance in aged Bigenic cohorts was grossly similar to controls (data not shown). Interestingly, ileal crypt depth in adult BigenicNS mice was 42% greater than age-matched WT controls, indicating that ileal crypt hyperplasia was maintained despite this outcome (Figure 2D). TH17 cell accumulation also remained higher than controls for both the ileal and colonic lamina propria and for the mLN of adult BigenicNS mice (Figure 2E–G). In marked contrast, adult BigenicS mice had ileal crypt depths similar to control mice (Figure 2D) and their colonic tissues showed histopathologic features consistent with colitis (Figure 2H). In further contrast to BigenicNS mice, the ileal and colonic lamina propria of adult BigenicS mice accumulated more TH17 cells along with TH1 and Treg cells (Figure 2E–G). Concordant with a diagnosis-associated increase in TH1 cells, adult BigenicS mice showed elevated levels of IFNγ in the serum (Table S1). Thus, adult BigenicS mice developed a broader colitic disease state, marked by loss of ileal hyperplasia and a more pronounced mucosal accumulation of CD4+T cells. By contrast, adult BigenicNS mice retained the abnormal features of juvenile mice despite becoming less likely to manifest symptomatology with age, indicating that the mechanism underlying TH17-associated ileal hyperplasia was insufficient to precipitate disease.
Ileal-reactive Treg cells associate with a failure to develop colitic disease
One strength of our model is the capacity to study the developmental fate of both ileal-reactive 3A9+CD4+T cells and the polyclonal 3A9−CD4+T cell population. Frequency and number of 3A9+ clones were decreased among the CD4+T cell population in Bigenic mice relative to 3A9 mice, consistent with negative selection in the thymus (Figure S2A–B & Table S2). To determine if the CD4+T cells from juvenile Bigenic ilea were enriched in the 3A9+ clonotype, we compared the frequency of 3A9+ clones between ileal and colonic CD4+T cell populations from individual mice. Within the Bigenic cohort, the 3A9+ clonotype was more frequent among ileal CD4+T cells. This stands in contrast to control 3A9 mice lacking the mHEL transgene, where 3A9+ clones were more frequent among colonic CD4+T cells (Figure 3A). Next we determined the activation status of 3A9− and 3A9+Tconv clones in the mLN. Within individual juvenile Bigenic mice, 3A9−Tconv cells were 2x more likely to have an effector/memory phenotype than 3A9+Tconv cells (Figure 3B). 3A9+ clones were less frequent among colonic CD4+Tconv cells from BigenicS mice (Figure S2C) and Bigenic CD4+Tconv cells transferred colitis to Rag1−/− mice that lack the HD5-mHEL transgene (Figure S3A–B). Furthermore, 3A9− clonotypes account for most of the TH17 accumulation in the mLN and ileum (Figure S2D–E). These findings indicate that more 3A9+ clones are found among CD4+T cells of the ileal mucosa, yet 3A9− clonotypes predominate, favor pro-inflammatory lineages and are more likely responsible for colonic disease.
Figure 3. mLN 3A9+Treg cells increase with age in BigenicNS mice.
(A) Ratio of 3A9 clonotype abundance among ileal CD4+T cells relative to 3A9 clonotype abundance among colonic CD4+T cells. Ratio calculated from FACS analysis of paired ileum and colon of juvenile 3A9 (n=11) and Bigenic (n=14) mice.
(B) TEM surface phenotype among mLN TCRβ+CD4+CD8−Foxp3− (Tconv) cell populations after sub-stratification into 3A9+ and 3A9− clonotype groups. Paired 3A9− and 3A9+ clonotype groups from same mouse indicated with connecting line and significance for paired samples reflects result of Wilcoxon matched-pairs signed rank test. Juvenile WT (n=25), 3A9 (n=19) and Bigenic (n=22) mice shown.
(C) Treg (Foxp3+) lineage commitment among mLN CD4+T cell populations after sub-stratification into 3A9+ and 3A9− clonotype groups. Analysis and cohort same as detailed for panel B.
(D) 3A9−Treg (left) and 3A9+Treg (right) cell numbers in mLN of Juvenile (3A9 n=19; Bigenic n=22) and early adult (3A9 n=8; BigenicNS n=8; BigenicS n=11) mice.
In contrast to 3A9−CD4+T cells, 60% of 3A9+CD4+T cells from juvenile Bigenic mLNs expressed Foxp3, making them 75x more likely to be Treg cells than the 3A9+CD4+T cells from the mLN of 3A9 mice (Figure 3C). 3A9+Treg cells also accumulated in mLN and ileum of Bigenic mice (Figure S2F–G, Table S2). Furthermore, 3A9+Treg cells increased in the mLN of adult BigenicNS mice relative to both juvenile and adult BigenicS mice (Figure 3D). These clonotype studies suggest that despite early overproduction of 3A9−TH17 cells, the in vivo determinants of cell fate in BigenicNS mice favor tolerogenic lineage-commitment for self-reactive T cells, in contrast to BigenicS mice. Expansion of ileal-reactive Treg cells also suggests a mechanism whereby Bigenic mice reduce the incidence of colitic disease with age.
IL-17A and IFNγ are required for ileal-reactive Treg accumulation
As Bigenic mice age, they either accumulate ileal-reactive Treg cells or develop colitic disease linked to a broad increase in mucosal TH17 cells. This led us to examine how IL-17A contributed to ileal-reactive Treg accumulation and the incidence of colitic disease by breeding Il17a−/−Bigenic mice. The absence of IL-17A had little effect on the incidence of the wasting disease or on weight loss following diagnosis (Figure 4A–B). Similar to BigenicNS mice, ileal crypt hyperplasia remained in Il17a−/−BigenicNS mice, indicating that IL-17A was not necessary for this tissue response (Figure 4C). As compared to Il17a+/+BigenicS mice, Il17a−/−BigenicS mice manifested colitis yet with greater distension of the lamina propria by infiltrating cells and more frequent lymphoid aggregates (Figure 4D, Figure S4A). In parallel, both the ileal and colonic lamina propria in Il17a−/−BigenicS mice accumulated more TH1 and Treg cells as compared to Il17a+/+BigenicS mice (Figure 4E–F). Finally, Il17a−/−BigenicNS mice failed to accumulate 3A9+Tregs in the mLN despite unchanged 3A9−Treg accumulation (Figure 4G). These data indicate that IL-17A limits TH1 accumulation in the mucosae of BigenicS mice and is required for ileal-reactive Treg accumulation in BigenicNS mice, consistent with a protective role.
Figure 4. IL-17A required for tolerance to HEL antigen but not wasting disease.
(A) Prevalence of a wasting phenotype among Il17a−/− (n=35) and Il17a+/+ (n=111) Bigenic mice.
(B) Weight change rate following initial manifestation of the wasting phenotype for Il17a−/− (n=54) and Il17a+/+ (n=18) Bigenic mice reaching early adult age.
(C and D) Ileal crypt depths (C) and colitis scores (D) for late adult Il17a−/−BigenicNS (n=10), Il17a−/−BigenicS (n=7), BigenicNS (n=11), and BigenicS (n=17) mouse cohorts.
(E and F) Numbers of TH1 and Treg cells from ileum (E) and colon (F). Early adult Il17a−/−BigenicNS (n=5), Il17a−/−BigenicS (n=11), BigenicNS (n=9), and BigenicS (n=9) mice shown.
(G) 3A9+Treg and 3A9−Treg cell numbers from mLN of early adult Il17a−/−BigenicNS (n=5), Il17a−/−BigenicS (n=11), BigenicNS (n=8), and BigenicS (n=11) mice.
(H and I) In vivo polarization of naïve polyclonal Thy1.1+Tconv cells and 3A9+Thy1.1+Tconv cells in newly weaned Il17a−/− (n=8) and Il17a+/+ (n=8) Bigenic mice. Activation (%TEM) among Thy1.1+CD4+Tconv cell population (H) and lineage commitment (left TH17; right TH1) among CD44+Thy1.1+CD4+Tconv cell populations (I) after sub-stratification into 3A9+ and 3A9− clonotype groups. Paired 3A9− and 3A9+ clonotype groups from same mouse indicated with connecting line and significance for paired samples reflects result of Wilcoxon matched-pairs signed rank test.
To better characterize the early regulatory environment of Il17a−/−Bigenic mice, we transferred a 1×106 cells of a 1:1 mixture containing Thy1.1+3A9+ and Thy1.1+3A9− (polyclonal) naïve Tconv cells into newly weaned Thy1.1−/−Il17a−/−Bigenic mice. After seven days, approximately 65–70% of the recovered Thy1.1+3A9− population were activated when recovered from either Il17a−/− or Il17a+/+Bigenic mice (Figure 4H). Activation largely favored a TH17 lineage in both Bigenic strains (Figure 4I). 3A9+Tconv cells recovered from Il17a+/+Bigenic mice remained naïve and the small frequency that expressed activation markers did not produce either IL-17A or IFNγ (Figure 4H–I). In contrast, ~70% of 3A9+Tconv cells recovered from Il17a−/−Bigenic mice were activated and favored the development of a TH17 cell phenotype (Figure 4H–I). These findings indicate that the regulatory environment of Il17a−/−Bigenic mice fails to prevent the pro-inflammatory development of ileal-reactive naïve CD4+T cells.
The infiltration of TH1 cells in the lamina propria of BigenicS mice suggested that elimination of the TH1-produced cytokine IFN-γ might facilitate development of ileal-reactive Treg cells. To test this possibility, we bred Ifng−/−Bigenic mice and monitored disease progression. Surprisingly, nearly all (98%) Ifng−/−Bigenic mice initiated disease within the juvenile period (Figure 5A–B) revealing a dominant role for IFNγ in preventing morbidity. Additionally, weight loss was non-remitting, ileal crypts were shorter, colitis scores higher, and the lamina propria from both tissues accumulated more TH17 cells in Ifng−/−Bigenic mice than in age-matched Ifng+/+Bigenic controls (Figure 5C–G). Treg cell numbers from the ilea of Ifng−/−Bigenic mice were not increased (Figure 5F) and furthermore, the mLN from Ifng−/−Bigenic mice showed reduced accumulation of both 3A9+ and 3A9− Treg cells (Figure 5H). Next, we studied the regulatory environment in newly weaned Ifng−/−Bigenic mice by applying the co-transfer method used for Il17a−/−Bigenic mice. 3A9+Tconv cells recovered from Ifng−/−Bigenic mice were mostly activated and favored a TH17-lineage (Figure 5I–J). Similarly, the recovered 3A9−Tconv cells were more likely to be activated, and once activated, more consistently expressed IL-17A than when transferred into Ifng+/+Bigenic mice (Figure 5I–J). These findings demonstrate that both IL-17A and IFNγ play protective roles in the Bigenic model, given that their absence led to an inability to regulate ileal-reactive naïve CD4+T cells prior to the onset of colitic disease.
Figure 5. IFNγ required for tolerance to HEL antigen and preventing acute wasting disease.
(A) Representative growth curves for two Ifng−/−Bigenic mice exhibiting the acute weight loss phenotype. Dashed vertical line indicates when mouse first showed two standard deviations more weight loss than age and sex-matched control mice.
(B) Prevalence of a wasting phenotype among Ifng−/− (n=49) and Ifng+/+ (n=159) Bigenic mice during the juvenile period.
(C) Weight change rate during the juvenile period following initial manifestation of the wasting phenotype for Ifng−/− (n=46) and Ifng+/+ (n=41) Bigenic mice.
(D and E)1 Ileal crypt depths (D) and colitis scores (E) for juvenile Ifng−/− (n = 16) and Ifng+/+ (n=19) Bigenic cohorts.
(F and G)1 Numbers of TH17 and Treg cells from ileum (F) and colon (G). Juvenile Ifng−/−(n=10) and Ifng+/+ (n=14) Bigenic mice shown.
(H)1 3A9+Treg and 3A9−Treg cell numbers from mLN of juvenile Ifng−/− (n=25) and Ifng+/+ (n=22) Bigenic mice shown.
(I and J) In vivo polarization of naïve polyclonal Thy1.1+Tconv cells and 3A9+Thy1.1+Tconv cells in newly weaned Ifng−/− (n=10) and Ifng+/+ (n=8) Bigenic mice. Activation (%TEM) among Thy1.1+CD4+Tconv cells (I) and lineage commitment (TH17 or TH1) among CD44+Thy1.1+CD4+Tconv cells (J) after sub-stratification into 3A9+ and 3A9− clonotype groups. Paired 3A9− and 3A9+ clonotype groups from the same mouse indicated with connecting line and significance for paired samples reflects the result of Wilcoxon matched-pairs signed rank test.
1In 5D-5E, all Ifng−/−Bigenic mice were symptomatic and ~90% required euthanasia before the juvenile age.
Accelerated disease initiation in Ifng−/−Bigenic mice requires IL-17A and IL-23
The overproduction of TH17 cells associated with the accelerated disease initiation and progression of Ifng−/−Bigenic mice led us to consider a pathogenic role for IL-17A in this genotype. Consistent with our hypothesis, deficiency of IL-17A in Ifng−/−Bigenic mice was protective, as the absence of both cytokines reduced the incidence of wasting disease as compared to Ifng−/−Bigenic controls (Figure 6A). However, after developing symptoms, Ifng−/−Il17a−/−BigenicS mice and Ifng−/−BigenicS showed similar weight loss (Figure 6B). Ileal crypt hyperplasia remained a feature of Il17a−/−Ifng−/−BigenicNS mice, demonstrating that neither cytokine was required for this tissue response (Figure 6C). Interestingly, colitis was more severe than in Ifng−/−BigenicS mice, largely due to increasingly distorted mucosal architecture and a ~3-fold increase in crypt abscesses (Figure 6D, Figure S4B). These findings indicate that in the TH17-overproducting Ifng−/−Bigenic mice, IL-17A promotes disease initiation, yet also limits the severity of the colitis that subsequently develops.
Figure 6. IL-17A and IL-23 promote increased disease incidence in Ifng−/−Bigenic mice.
(A) Prevalence of a wasting phenotype among Il17a−/−Ifng−/−Bigenic (n=39), Ifng−/−Bigenic (n=38) and Bigenic (n=159) mice during the juvenile period.
(B) Weight change rate during the juvenile period following initial manifestation of the wasting phenotype for Il17a−/−Ifng−/−Bigenic (n=29), Ifng−/−Bigenic (n=46) and Bigenic (n=41) mice.
(C and D) Ileal crypt depths (C) and colitis scores (D) for juvenile Il17a−/−Ifng−/−BigenicNS (n=6), Il17a−/−Ifng−/−BigenicS (n=18), Ifng−/−Bigenic (n=17) and Bigenic (n = 19) cohorts. Symptomatic cohorts include mice euthanized before juvenile age (Il17a−/−Ifng−/−Bigenic n=10; Ifng−/−Bigenic n=15).
(E) Prevalence of a wasting phenotype among IL-23R blockade treated Ifng−/−Bigenic (21A4; n=15), isotype control treated Ifng−/−Bigenic (ISO; n=9), Ifng−/−Bigenic (n=50) and Bigenic (n=157) mice during the juvenile period.
(F) Weight change rate during the juvenile period following initial manifestation of the wasting phenotype for 21A4 (n=4), ISO (n=9), Ifng−/−Bigenic (n=50) and Bigenic (n=157) mice.
(G and H) Ileal crypt depths (G) and colitis scores (H) for juvenile 21A4 (n=10), ISO (n = 9), Ifng−/−Bigenic (n=16) and Bigenic (n=19) mice. Symptomatic mouse cohorts include mice euthanized before juvenile endpoint (ISO n=6; Ifng−/−Bigenic n=15).
(I) 3A9+Treg and 3A9−Treg cell numbers from mLN. Juvenile 21A4 (n=10), ISO (n=9), Ifng−/−Bigenic (n=25) and Bigenic (n=22) mice shown. Most Ifng−/−Bigenic mice required euthanasia before juvenile endpoint (n=21).
Collectively, our studies of Il17a−/− and Il17a−/−Ifng−/−Bigenic mice implicate both pathogenic and protective mechanisms that are dependent upon IL-17A. Given that IL-23, a constitutive product of ileal dendritic cells24, is known to increase the pathogenic potential of IL-17A-producing lymphocytes25,26, we tested whether IL-23R blockade would prevent disease in Ifng−/−Bigenic mice. We began IL-23R blockade (21A4 treatment) at weaning and maintained this blockade through the juvenile period. 21A4-treatment reduced disease incidence and abrogated the progressive weight loss in the few mice that were diagnosed (Figure 6E–F). Ileal crypts in 21A4-treated Ifng−/−Bigenic mice showed marked hyperplasia and the average crypt lengths were also increased relative to age-matched Ifng+/+Bigenic control mice (Figure 6G). Importantly, 21A4 treatment also prevented colitis in Ifng−/−Bigenic mice (Figure 6H). 21A4 treatment had no effect on numbers of mLN TH17 cells (data not shown), yet mLN contained more 3A9−Treg cells with 3A9+Treg cells approaching juvenile Ifng+/+Bigenic mouse levels (Figure 6I). These results demonstrate that in the setting of excessive TH17 cell production, IL-23 prevents ileal hyperplasia, promotes acute colitic disease and antagonizes Treg cell accumulation.
nTreg transfer blocks colitic disease, TH17 production and ileal hyperplasia
Neither cytokine deficiency nor IL-23R blockade prevented ileal hyperplasia in BigenicNS mice, indicating alternative mechanisms were responsible for this early tissue response. TH17 cell development can be triggered by SFB, however fecal SFB showed no relation to genotype or symptomatology (Figure S5A–B). As Bigenic mice produce fewer nTreg cells than WT control mice (Table S2, Figures 2G and S2B), we hypothesized that reduced nTreg production led to the early TH17-associated ileal hyperplasia (Figure 1C–D) and allowed a dysregulation of microbiota-reactive 3A9−CD4+Tconv cells in symptomatic mice (Figures S5C–D). To test this possibility, we transferred 5×105 polyclonal nTreg cells isolated by cell sorting from Foxp3EGFP B6.AKR mice into newly-weaned Bigenic and Ifng−/−Bigenic mice and studied them through the juvenile period. Supplementation with nTreg cells reduced the incidence of disease in both Bigenic and Ifng−/−Bigenic mice during the juvenile period (Figure 7A). Additionally, the few nTreg-treated Ifng−/−Bigenic mice that manifested a weight abnormality gained weight after diagnosis (Figure 7B). In both genotypes, nTreg transfer reduced ileal hyperplasia, prevented colitis and lowered TH17 cell numbers in the mLN (Figure 7C–E). This was the first intervention that simultaneously prevented colitic disease and ileal hyperplasia in Bigenic mice. Finally, treating Bigenic mice with nTregs also reduced 3A9+Treg cells in the mLN (Figure 7F) suggesting that the ileal phenotype present in BigenicNS mice is representative of a compensatory tolerogenic process.
Figure 7. nTreg treatment prevents ileal and colonic inflammation and 3A9+iTreg treatment slows disease.
(A) Prevalence of a wasting phenotype among nTreg-treated Bigenic (n=18), nTreg-treated Ifng−/−Bigenic (n=12), Ifng−/−Bigenic (n=47) and Bigenic (n=167) mice during the juvenile period.
(B) Weight change rate during the juvenile period following initial manifestation of the wasting phenotype for nTreg-treated Ifng−/−Bigenic (n=5), Ifng−/−Bigenic (n=46) and Bigenic (n=41) mice.
(C and D)1 Ileal crypt depths (C) and colitis scores (D) for juvenile nTreg-treated Bigenic (n=19), nTreg-treated Ifng−/−Bigenic (n=12), Ifng−/−Bigenic (n=17) and Bigenic (n=19) cohorts.
(E and F)1 Numbers of TH17 (E) and 3A9+Treg (F) cells from mLN. Juvenile nTreg-treated Ifng−/−Bigenic (n=12), nTreg-treated Bigenic (n=16), Ifng−/−Bigenic (n=21) and Bigenic (n=21) mice shown.
(G) Prevalence of a wasting phenotype among 3A9+iTreg-treated Ifng−/−Bigenic (n=12), Ifng−/−Bigenic (n=47) and Bigenic (n=167) mice during the juvenile period.
(H) Weight change rate during the juvenile period following initial manifestation of the wasting phenotype for 3A9+iTreg-treated Ifng−/−Bigenic (n=9), Ifng−/−Bigenic (n=46) and Bigenic (n=41) mice.
(I) Foxp3 expression among transferred 3A9+iTreg cells at endpoint for treated Ifng−/−BigenicNS (n=3) and Ifng−/−BigenicS (n=9) mice (left). Expression from Ifng−/−BigenicS mice correlated to age of onset (right).
1In 7C-7F, all Ifng−/−Bigenic mice were symptomatic and ~90% required euthanasia before the juvenile age.
To examine the capacity of a monoclonal population of 3A9+Tregs cells to prevent disease, we transferred 5×105 in vitro derived 3A9+iTreg cells into newly weaned Ifng−/−Bigenic mice. 3A9+iTreg cell transfer reduced disease incidence (Figure 7G), though in mice that manifested disease, weight loss was similar to untreated Ifng−/−Bigenic mice (Figure 7H). Since Foxp3 expression is unstable in iTreg cells27, we assessed whether the maintenance of Foxp3 expression in the transferred cells was associated with the outcome. Recovered cells from non-symptomatic mice retained the highest frequency of Foxp3+ cells, and the time to disease onset in symptomatic mice was strongly associated with the maintenance of Foxp3 expression (Figure 7I). Together, these transfer studies support the notion that the TH17-associated ileal hyperplasia is a feature of a process that limits the impact of partial nTreg deficiency by skewing the differentiation of the self-reactive repertoire toward the Treg compartment.
DISCUSSION
Our new model of enterocolitis begins with a uniform set of disease determinants in juvenile mice. In adult mice, a spontaneous segregation occurs between the colitis associated with wasting disease and the ileal immunoregulatory state associated with normal growth. Thus, what begins as a continuum of shared susceptibility diverges with age to yield two phenotypically dichotomous outcomes. We conclude that the infiltrative processes active in the ilea of BigenicNS mice are insufficiently pathogenic to drive disease and instead reflect over-active homeostatic pathways compensating for decreased nTreg production. The central finding reported herein is that both IL-17A and IFNγ contribute to the maintenance of this homeostatic state and ultimately facilitate the generation of antigen-specific tolerance to the ileal mucosa. Furthermore, we contend that disease progression results from the hypersensitivity of this over-active homeostatic process to normal immunomodulatory signals, such as IL-2328,29, that limit mucosal tolerance to luminal bacteria (Figure S6).
Treg cell abnormalities are reported for individuals with active IBD10 and defects in Treg cells cause colitis in mouse models. In both settings, Treg cell supplementation has shown clinical efficacy30. A relative Treg deficiency permitted disease in our Bigenic model given that thymic nTreg production was low and supplementation with nTreg cells prevented all disease manifestations. Interestingly, nTreg infusion also prevented ileal-reactive Treg accumulation and supplementation with in vitro generated 3A9+iTreg cells alone also showed efficacy in preventing disease. Thus, while the Bigenic model may begin as a partial nTreg deficiency, some mice mold the repertoire of this numerically constrained Treg population to prevent disease progression. We did not address whether ileal-reactive Treg cells in BigenicNS mice are thymically derived or peripherally induced, however their reduced numbers following nTreg infusion suggests that they accumulate in response to a peripheral inflammatory process. Regardless of the ontogeny of these ileal-reactive Treg cells, our findings imply that Treg-mediated tolerance targeted at an antigen found only in the ileum is sufficient to prevent inflammatory disease in the colon.
Other enterocolitis models show highly penetrant disease where crypt hyperplasia is associated with morbidity31,32. In contrast, we found that crypt hyperplasia was a characteristic of the ilea from Bigenic mice that lacked disease. Adaptive immune responses that judiciously target commensal organisms without dysregulating mucosal tolerance are a prominent feature of the healthy ileum18,22,33. Similarly, ilea of Bigenic mice can maintain mucosal tolerance while exhibiting this abnormal TH17-associated crypt hyperplasia. By targeting an ileal self-antigen with CD4+T cells, we made ileal paracrine signaling more likely to impact CD4+T cell responses that develop in Bigenic mice. Studies from Esplugues et al showed that intestinal trafficking can reduce the pathogenic activity of CD4+T cells34. Thus, the accumulation of ileal-reactive Treg cells and declining incidence of colitic disease with age may reflect the systemic impact of ileal paracrine signaling. Findings from a related Bigenic system, where the mHEL target antigen was expressed in tissues other than the gastrointestinal (GI) mucosa, highlight the importance of specifically targeting the ileum. Shih et al characterized a spontaneous wasting disease where relative nTreg deficiency dysregulated 3A9−CD4+T cells and lead to colitis, however the authors identified very few mice without disease and did not report ileal involvement35. This implies that the ileal microenvironment is essential for BigenicNS mice to compensate for the relative nTreg deficiency unmasked in 3A9 Bigenic systems.
The ilea of non-symptomatic Bigenic mice accumulated more TH17 cells than control mice suggesting that TH17 cells may also facilitate maintenance of homeostasis. Despite being identified by their association with IL-23-dependant autoimmune pathology36, TH17 cells share a developmental axis with iTreg cells and can also manifest immunoregulatory phenotypes37. TH17-lineage mapping uncovered a prominent IL-23-independent role for TH17 cells in the induction of T cell-dependent IgA responses22 and conditional deletion of Il17ra on the intestinal epithelium showed that TH17 cells also contribute to transcytosis of IgA33. Both studies highlight important contributions of TH17 cells to homeostatic processes of intestinal tissues. Interestingly, TH17 cells produced in the setting of inflammatory disease that home to and are conditioned by the small intestine can acquire a regulatory phenotype34. Our studies support this role for TH17 cells in homeostasis, as Il17a−/−Bigenic mice failed to accumulate ileal-reactive Treg cells in the mLN and were unable to prevent activation of naïve ileal-reactive CD4+T cells. We recently reported a similar positive association between Treg and TH17 lineages as both were co-produced in the lymphopenic colitis model when mice were pre-treated with M2-polarized macrophages38. Though a number of studies indicate that IL-17A can limit the severity of bowel inflammation8,39, our data demonstrate that protective activity is in part due to the accumulation of mucosa-reactive Treg cells. Given more recent studies showing that IL-17A limits the growth of pro-inflammatory commensal microbes33,40, IL-17A deficiency may result in dysregulated ileal-reactivity secondary to dysbiosis.
IL-17A does not contribute to pathogenesis in a consistent way across the various models of inflammatory disease9,39,41. Furthermore, even when studying the same colitis model, genetic deletion of IL-17A and antibody blockade showed opposite effects on the outcome9,39. These contradictory findings likely reflect the pleiotropic nature of IL-17A and thus suggest that its pathogenic potential is context-dependent. Opposing roles at different stages of disease have been described42 and this may explain why we did not see an increased incidence of disease in Il17a−/− mice despite reduced ileal tolerance. Our model exhibits discrete stages and thus, it is possible that IL-17A promotes homeostasis yet also contributes to pathogenesis once homeostasis is disrupted. This interpretation is supported by Il17a+/+Ifng−/−Bigenic mice where the reduced ileal tolerance is associated with an IL-17A-dependent rise in the incidence of colitic disease. Thus, we expect that outcomes for individual Bigenic mice also depend on whether the juvenile mucosal environment favors the homeostatic development of IL-17A-producing cells or pathogenic development, such as occurs in TH17 cells exposed to IL-2343,44.
Both Il17a+/+ and Il17a−/−BigenicS mice had increased TH1 cells in the GI lamina propria yet IFNγ was essential for preventing highly penetrant and accelerated disease. IFNγ directly inhibits TH17 development by reducing IL-23R expression36 and accordingly, Ifng−/−Bigenic mice also showed excessive TH17 production. IL-17A proved necessary for the high disease penetrance and progression was entirely dependent upon IL-23 signaling during the juvenile period. Thus, increased TH17 cell levels also appear to sensitize mice to colitis in Bigenic mice.
Blocking IL-23 in Ifng−/−Bigenic mice yielded many interesting findings with the first being the restored ileal crypt hyperplasia. The average crypt length was higher than that observed in any other Bigenic cohort, indicating a further exaggeration of the ileal homeostatic process seen in BigenicNS mice. We also observed increased Treg production following IL-23 blockade, consistent with the link between Treg production and ileal hyperplasia in Bigenic mice and with the inhibition of IL-23 in other models29. Given the exaggerated production of TH17 cells in Ifng−/−Bigenic mice subjected to IL-23R blockade, our findings suggest that non-pathogenic TH17 cells promote ileal crypt hyperplasia and regulatory T cell production. This raises the possibility for an unconventional treatment strategy whereby the stimulation of TH17 cell production in the setting of IL-23 blockade could restore durable mucosal tolerance through the mobilization of homeostasis-promoting TH17 cells and antigen-specific Treg cells.
MATERIALS AND METHODS
Animals
HD5-mHEL mice were created similarly to previously reported CCSP-mHEL/Hb transgenic mice45. A detailed description of the generation of this line all other lines used for breeding and adoptive transfer experiments can be found in the Supplemental Methods. The Animal Resource Committee at the Medical College of Wisconsin approved all animal experiments.
Wasting phenotype diagnosis
All progeny from experimental crosses were weighed every other day starting the day of weaning and ending at euthanasia. For days when an individual mouse was not weighed, we estimated the mouse’s weight via a linear interpolation from the two nearest weight measurements. We applied three weight-based criteria to diagnose the presence of either poor growth or excessive weight loss symptomatology. These criteria are detailed in the Supplemental Methods.
Lymphocyte isolation
Lymphocytes were isolated from the entire thymus, spleen and mLN. Lamina propria lymphocytes were isolated from the entire colon and distal 15 cm of the small intestine. Extraction procedures detailed further in Supplemental Methods.
Flow cytometry, cell sorting and adoptive transfer
Isolated lymphocytes were stained using both surface marker and intracellular cytokine staining panels as previously described45. A four-laser custom LSRII was used to collect FACS data and FlowJo software was used for gating analysis. Primary and cultured cells were sorted using BD FACS Aria IIu as previously descried and all adoptive transfers were i.p. injected. Further of these methods are provided in the Supplemental Methods section.
Histology
The entire colon and distal 4.5 cm of the small intestine were fixed in Zn Formalin. Post-fixation tissue processing, staining and slide scanning were performed by the Children’s Research Institute Histology Core at MCW. Depths for ~150 crypts were measured for each scanned tissue section. Colitis was scored by a certified anatomic pathologist (MS) on basis of inflammation depth (0–2), epithelial cell reactive changes (0–3), mucosal architectural distortion (0–3) and inflammatory cell density in the lamina propria distention (0–3) without prior knowledge of the tissue genotype or disease history. Lymphoid aggregate foci and crypt aggregates were directly quantitated on scanned slides, reduced to 3-point scale and included in the aggregate score to give a max colitis score of 17. Chromogenic in situ hybridization was applied to visualize the location of mHEL-expressing cells. A detailed description of tissue staining, image analyses and colitis scoring is provided in the Supplemental Methods.
Additional methods
Detailed descriptions of the methods for serum studies, IL-23R blockade, and 3A9+iTreg production can be found in the Supplemental Methods.
Statistics
Median and interquartile range shown on all graphs for univariate statistical analyses. All statistical tests were done on Prism 7. Outliers were removed from all examined datasets after Prism 7 Robust regression and Outlier removal analysis applying a ROUT coefficient (Q) of 1%. The non-parametric Kruskal-Wallis test was applied for datasets with more than two comparison groups and if p was less than 0.05 followed by Mann-Whitney test post-hoc to identify which groups account for significant findings. Differences between the prevalence vs age curves were detected using the Mantel-Cox Log-rank test. Significance thresholds were marked with the Prism 7 symbol convention: * for 0.05 > p > 0.01, ** for 0.01 > p > 0.001, *** for 0.001 > p.
Supplementary Material
ACKNOWLEDGEMENTS
We thank Paul Allen for the gift of 3A9 mice and Daniel Cua for the gift of the 21A4 (αIL23R) antibody. We also thank Dipica Haribhai, Erica Schmitt, Lily Allison, and Lauren Drobyski for technical assistance. This work was supported by grants from the following sources: R01 AI085090 (CBW), F32AI092977 (CGM), a Senior Research Award from the Crohn’s and Colitis Foundation (CBW), the D.B. and Marjorie Reinhart Family Foundation Endowed Chair in Rheumatology (CBW), and from the Children’s Hospital of Wisconsin (CBW).
References
- 1.Khor B, Gardet A & Xavier RJ Genetics and pathogenesis of inflammatory bowel disease. Nature 474, 307–317, doi: 10.1038/nature10209 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Sandborn WJ et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 56, 1232–1239, doi: 10.1136/gut.2006.106781 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Billioud V, Sandborn WJ & Peyrin-Biroulet L Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol 106, 674–684, doi: 10.1038/ajg.2011.60 (2011). [DOI] [PubMed] [Google Scholar]
- 4.Sandborn WJ et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 135, 1130–1141, doi: 10.1053/j.gastro.2008.07.014 (2008). [DOI] [PubMed] [Google Scholar]
- 5.Hueber W et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693–1700, doi: 10.1136/gutjnl-2011-301668 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Reinisch W et al. Fontolizumab in moderate to severe Crohn’s disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 16, 233–242, doi: 10.1002/ibd.21038 (2010). [DOI] [PubMed] [Google Scholar]
- 7.Powrie F et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1, 553–562 (1994). [DOI] [PubMed] [Google Scholar]
- 8.O’Connor W Jr. et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 10, 603–609, doi: 10.1038/ni.1736 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Ito R et al. Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. Biochem Biophys Res Commun 377, 12–16, doi: 10.1016/j.bbrc.2008.09.019 (2008). [DOI] [PubMed] [Google Scholar]
- 10.Maul J et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 128, 1868–1878 (2005). [DOI] [PubMed] [Google Scholar]
- 11.Mowat AM & Agace WW Regional specialization within the intestinal immune system. Nat Rev Immunol 14, 667–685, doi: 10.1038/nri3738 (2014). [DOI] [PubMed] [Google Scholar]
- 12.Johansson ME et al. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A 105, 15064–15069, doi: 10.1073/pnas.0803124105 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Ermund A, Schutte A, Johansson ME, Gustafsson JK & Hansson GC Studies of mucus in mouse stomach, small intestine, and colon. I. Gastrointestinal mucus layers have different properties depending on location as well as over the Peyer’s patches. Am J Physiol Gastrointest Liver Physiol 305, G341–347, doi: 10.1152/ajpgi.00046.2013 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Meyer-Hoffert U et al. Secreted enteric antimicrobial activity localises to the mucus surface layer. Gut 57, 764–771, doi: 10.1136/gut.2007.141481 (2008). [DOI] [PubMed] [Google Scholar]
- 15.Vaishnava S et al. The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine. Science 334, 255–258, doi: 10.1126/science.1209791 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Bevins CL & Salzman NH Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. Nat Rev Microbiol 9, 356–368 (2011). [DOI] [PubMed] [Google Scholar]
- 17.Kolls JK, McCray PB Jr. & Chan YR Cytokine-mediated regulation of antimicrobial proteins. Nat Rev Immunol 8, 829–835, doi: 10.1038/nri2433 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Bunker JJ et al. Innate and Adaptive Humoral Responses Coat Distinct Commensal Bacteria with Immunoglobulin A. Immunity 43, 541–553, doi: 10.1016/j.immuni.2015.08.007 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Macpherson AJ, Hunziker L, McCoy K & Lamarre A IgA responses in the intestinal mucosa against pathogenic and non-pathogenic microorganisms. Microbes Infect 3, 1021–1035 (2001). [DOI] [PubMed] [Google Scholar]
- 20.Tsuji M et al. Preferential generation of follicular B helper T cells from Foxp3+ T cells in gut Peyer’s patches. Science 323, 1488–1492, doi: 10.1126/science.1169152 (2009). [DOI] [PubMed] [Google Scholar]
- 21.Wang S et al. MyD88 Adaptor-Dependent Microbial Sensing by Regulatory T Cells Promotes Mucosal Tolerance and Enforces Commensalism. Immunity 43, 289–303, doi: 10.1016/j.immuni.2015.06.014 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Hirota K et al. Plasticity of Th17 cells in Peyer’s patches is responsible for the induction of T cell-dependent IgA responses. Nat Immunol 14, 372–379, doi: 10.1038/ni.2552 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Kelly MN et al. Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection. Infect Immun 73, 617–621, doi: 10.1128/IAI.73.1.617-621.2005 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Becker C et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest 112, 693–706, doi: 10.1172/JCI17464 (2003). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.McGeachy MJ & Cua D IL-23 is vital for effector Th17 cell function in vivo. Cytokine 39, 26–27, doi: 10.1016/j.cyto.2007.07.102 (2007). [DOI] [Google Scholar]
- 26.McGeachy MJ et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 10, 314–324, doi: 10.1038/ni.1698 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Schmitt EG et al. IL-10 produced by induced regulatory T cells (iTregs) controls colitis and pathogenic ex-iTregs during immunotherapy. J Immunol 189, 5638–5648, doi: 10.4049/jimmunol.1200936 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Mangan PR et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441, 231–234, doi: 10.1038/nature04754 (2006). [DOI] [PubMed] [Google Scholar]
- 29.Izcue A et al. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 28, 559–570, doi: 10.1016/j.immuni.2008.02.019 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Desreumaux P et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn’s disease. Gastroenterology 143, 1207–1217 10.1053/j.gastro.2012.07.116 (2012). [DOI] [PubMed] [Google Scholar]
- 31.Matsumoto S et al. Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain. Gut 43, 71–78 (1998). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F & Kollias G Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10, 387–398 (1999). [DOI] [PubMed] [Google Scholar]
- 33.Kumar P et al. Intestinal Interleukin-17 Receptor Signaling Mediates Reciprocal Control of the Gut Microbiota and Autoimmune Inflammation. Immunity 44, 659–671, doi: 10.1016/j.immuni.2016.02.007 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Esplugues E et al. Control of TH17 cells occurs in the small intestine. Nature 475, 514–518, doi: 10.1038/nature10228 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Shih FF, Mandik-Nayak L, Wipke BT & Allen PM Massive thymic deletion results in systemic autoimmunity through elimination of CD4+ CD25+ T regulatory cells. J Exp Med 199, 323–335, doi: 10.1084/jem.20031137 (2004). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Harrington LE et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6, 1123–1132, doi: 10.1038/ni1254 (2005). [DOI] [PubMed] [Google Scholar]
- 37.McGeachy MJ et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 8, 1390–1397, doi: 10.1038/ni1539 (2007). [DOI] [PubMed] [Google Scholar]
- 38.Haribhai D et al. Alternatively Activated Macrophages Boost Induced Regulatory T and Th17 Cell Responses during Immunotherapy for Colitis. J Immunol 196, 3305–3317, doi: 10.4049/jimmunol.1501956 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Ogawa A, Andoh A, Araki Y, Bamba T & Fujiyama Y Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol 110, 55–62, doi: 10.1016/j.clim.2003.09.013 (2004). [DOI] [PubMed] [Google Scholar]
- 40.Varelias A et al. Acute graft-versus-host disease is regulated by an IL-17-sensitive microbiome. Blood 129, 2172–2185, doi: 10.1182/blood-2016-08-732628 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Leppkes M et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 136, 257–267, doi: 10.1053/j.gastro.2008.10.018 (2009). [DOI] [PubMed] [Google Scholar]
- 42.Odobasic D et al. Interleukin-17A promotes early but attenuates established disease in crescentic glomerulonephritis in mice. Am J Pathol 179, 1188–1198, doi: 10.1016/j.ajpath.2011.05.039 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Yen D et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116, 1310–1316, doi: 10.1172/JCI21404 (2006). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Lee Y et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 13, 991–999, doi: 10.1038/ni.2416 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Schmitt EG et al. Chronic follicular bronchiolitis requires antigen-specific regulatory T cell control to prevent fatal disease progression. J Immunol 191, 5460–5476, doi: 10.4049/jimmunol.1301576 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.







